Nachrichten zur Halozyme Therapeutics Inc. Aktie

Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Call Transcript

…

Halozyme Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

…

Heres Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript

…

Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised

Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty…

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended June 2023,…

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 17.46% and 9.47%, respectively, for the quarter ended June 2023. Do…

Halozyme To Report Second Quarter 2023 Financial and Operating Results

SAN DIEGO, July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second…

Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock?

Halozyme Therapeutics (HALO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study

Halozyme (HALO) rises 5% after Roches late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology…

Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023....…

Halozyme gains as Piper Sandler upgrades despite Q1 miss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K HALOZYME THERAPEUTICS, For: May 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share…

Form 8-K HALOZYME THERAPEUTICS, For: May 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Halozyme To Report First Quarter 2023 Financial and Operating Results

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first…

Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest…

The Latest Analyst Ratings for Halozyme Therapeutics

Latest Ratings for HALO DateFirmActionFromTo Nov 2021Wells FargoMaintainsOverweight Nov 2021JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkMaintainsOutperform …

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Investors need to pay close attention to Halozyme Therapeutics (HALO) stock based on the movements in the options market lately....…

Form 8-K HALOZYME THERAPEUTICS, For: Mar 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 2.13% and 2.46%, respectively, for the quarter ended December 2022. Do…

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

Investors need to pay close attention to Halozyme (HALO) stock based on the movements in the options market lately....…

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the companys guidance fell short of Wall…

HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024

SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to…

Halozyme Therapeutics Stock Down 8% on 2022, 2023 Revenue Guidance

Halozyme Therapeutics Stock Down 8% on 2022, 2023 Revenue Guidance...…

Halozyme issues 2023 revenue, adj. EPS guidance below estimates, shares fall ~7%

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Halo Therapeutics stock drops following weak 2023 outlook

Halozyme Therapeutics Inc. HALO stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall…

Halozyme Provides 2023 Financial Guidance and Outlook

2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from…

Form 8-K HALOZYME THERAPEUTICS, For: Jan 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zacks.com featured highlights Halozyme Therapeutics, Arista Networks and Citizens Financial Group

Halozyme Therapeutics, Arista Networks and Citizens Financial Group have been highlighted in this Screen of The Week article....…

3 Stocks to Keep an Eye on for Earnings Growth in 2023

As 2023 approaches, its prudent to have a look at stocks like Halozyme Therapeutics (HALO), Arista Networks (ANET) & Citizens…

Halozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Epinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Epinephrine autoinjector market insights - Vendors: 15+, including Adamis Pharmaceuticals Corp., ALK Abello…

dpa-AFX ProFeed